Want to see TSE:BU full AI Analyst Report?
Top Page
Burcon Nutrascience
(TSX:BU)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$2.00
▲(15.61% Upside)
Action:Reiterated
Date:06/26/26
The score is primarily held back by weak financial performance—persistent losses, worsening cash burn, rising leverage, and negative equity. The earnings call adds support due to strong operational and commercialization momentum with explicit near-term targets, but mixed technicals and an unattractive loss-making valuation keep the overall score below average.
Positive Factors
Proprietary IP & licensing model
Burcon’s asset-light, IP-centered business model monetizes patented extraction and purification methods via licensing, JV commercialization and tech services. That structure supports scalable, recurring revenue potential and limited incremental capex per license, durable if partners scale production.
Negative Factors
Deteriorating balance sheet
A sharp rise in leverage and a move to negative shareholders’ equity weaken financial flexibility and increase refinancing and covenant risks. This degraded capital structure makes executing growth plans more dependent on external, potentially dilutive or costly financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary IP & licensing model
Burcon’s asset-light, IP-centered business model monetizes patented extraction and purification methods via licensing, JV commercialization and tech services. That structure supports scalable, recurring revenue potential and limited incremental capex per license, durable if partners scale production.
Read all positive factors
Burcon Nutrascience (BU) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$24.12M
Dividend YieldN/A
Average Volume (3M)6.58K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth493.78%
EPS Growth-15.51%
CountryCA
Employees14
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-1.11
Shares Outstanding12,692,942
10 Day Avg. Volume9,144
30 Day Avg. Volume6,578
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-4.05
Price to Sales (P/S)10.37
P/FCF Ratio-2.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)C$14.00M
Burcon Nutrascience Business Overview & Revenue Model
Company Description
Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensi...
How the Company Makes Money
Burcon makes money primarily by monetizing its intellectual property and related commercialization activities for plant-based protein ingredients. Key revenue streams include: (1) Licensing and royalties: licensing its patented/proprietary protein...
Burcon Nutrascience Earnings Call Summary
Earnings Call Date:Jun 24, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational progress and accelerating commercial traction — material revenue growth (nearly sixfold YoY), expanding customer pipeline (200+ projects and 30+ active buyers), repeat orders, and significant production improvements (60% higher daily production). Management also demonstrated cost discipline (G&A -23%, R&D -65%) and secured partial financing with partner and insider support. Primary challenges are the small absolute revenue base ($2.3M), remaining facility capital work and capacity planning, lengthy customer adoption cycles (9–18 months), and ongoing liquidity/financing considerations. Overall, the positive operational momentum and validated customer demand outweigh the early-stage risks and financing needs, but execution against scaling and profitability targets remains critical.Positive Updates
Revenue Growth
Fiscal 2026 revenues of $2.3 million, a nearly sixfold year-over-year increase (≈+400–500%), demonstrating a clear translation of operational progress into sales.
Negative Updates
Small Absolute Revenue Base
Despite large percentage growth, absolute revenue remains small at $2.3 million in fiscal 2026, highlighting an early commercial stage and ongoing need to scale volume materially to reach targets.
Read all updates
Q4-2026 Updates
Positive
Negative
Revenue Growth
Fiscal 2026 revenues of $2.3 million, a nearly sixfold year-over-year increase (≈+400–500%), demonstrating a clear translation of operational progress into sales.
Read all positive updates
Company Guidance
Management guided to achieve $10 million in sales in calendar 2026 and reach positive operating cash flow, forecasting significant quarter‑over‑quarter revenue growth into fiscal 2027 with fiscal Q1 expected to grow about 50% versus the prior quarter. They pointed to FY2026 operational results of $2.3 million revenue (nearly sixfold year‑over‑year), double‑digit QoQ growth in Q3 and Q4, a 60% higher daily production record versus the previous quarter, more than 200 active projects, 30+ active buyers, and three new product launches, alongside cost discipline (G&A down 23% and R&D down 65%). They also noted a $6.9 million convertible note financing (with $4.0 million closed in FY26), that the ProMan‑funded remaining capex will give the facility the capability to meet committed demand, and cited an 8–10% long‑term protein market CAGR.Burcon Nutrascience Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.26M | 381.40K | 184.36K | 363.91K | 171.47K |
| Gross Profit | -8.02M | -870.76K | 184.36K | 363.91K | 171.47K |
| EBITDA | -8.72M | -7.43M | -6.23M | -18.90M | -9.92M |
| Net Income | -14.25M | -8.26M | -7.45M | -25.36M | -10.26M |
Balance Sheet | |||||
| Total Assets | 22.99M | 30.66M | 12.91M | 9.90M | 29.35M |
| Cash, Cash Equivalents and Short-Term Investments | 950.53K | 7.28M | 4.20M | 1.46M | 7.00M |
| Total Debt | 24.42M | 22.40M | 6.67M | 5.17M | 73.14K |
| Total Liabilities | 28.79M | 23.71M | 7.76M | 5.76M | 1.10M |
| Stockholders Equity | -5.80M | 6.94M | 5.15M | 4.14M | 28.25M |
Cash Flow | |||||
| Free Cash Flow | -10.12M | -5.82M | -5.90M | -6.38M | -7.18M |
| Operating Cash Flow | -9.16M | -5.51M | -5.78M | -6.02M | -5.91M |
| Investing Cash Flow | -883.39K | -1.66M | -39.49K | -4.43M | -1.23M |
| Financing Cash Flow | 3.85M | 10.23M | 8.56M | 4.90M | 174.08K |
Burcon Nutrascience Technical Analysis
Negative
1.73
Price Trends
2.03
Negative
2.09
Negative
2.03
Negative
Market Momentum
-0.05
Positive
41.82
Neutral
20.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BU, the sentiment is Negative. The current price of 1.73 is below the 20-day moving average (MA) of 2.04, below the 50-day MA of 2.03, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.82 is Neutral, neither overbought nor oversold. The STOCH value of 20.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BU.
Burcon Nutrascience Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | C$49.40M | -17.44 | 47.73% | ― | 75.19% | 44.09% | |
47 Neutral | C$24.12M | -1.68 | -1208.82% | ― | 493.78% | -15.51% | |
45 Neutral | C$715.25K | -0.17 | -190.55% | ― | 3288.96% | 50.66% |
* Consumer Defensive Sector Average
TSE:BU
Burcon Nutrascience
1.87
-1.09
-36.82%
TSE:DTEA
DAVIDsTEA
0.95
-0.15
-13.64%
TSE:BABY
Else Nutrition Holdings
―
―
―
TSE:NPRA
Nepra Foods
0.34
0.24
240.00%
TSE:CULT
Cult Food Science Corp.
0.29
-0.46
-61.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.